溶质载体家族39成员6基因通过增加细胞内锌水平、激活磷脂酰肌醇3-激酶信号并上调转移调控基因促进食管癌细胞侵袭性
该研究探讨SLC39A6在食管鳞状细胞癌(ESCC)中的功能及其影响肿瘤进展的方式。在ESCC细胞系和HeLa细胞中过表达或敲低SLC39A6,分析体外增殖、集落形成、迁移和侵袭,并在裸鼠中建立异种移植瘤量化肿瘤体积和转移。获取2010年至2014年在中国接受食管切除术的94例患者的ESCC及癌旁正常食管组织。结果发现敲低SLC39A6降低ESCC细胞增殖和小鼠异种移植瘤转移;过表达SLC39A6的细胞细胞内锌水平显著增加、侵袭性更强,激活磷脂酰肌醇3-激酶信号至AKT丝氨酸/苏氨酸激酶1和丝裂原活化蛋白激酶1,并增加转移相关mRNA和蛋白(MMP1、MMP3、MYC、SLUG)表达。ESCC组织中SLC39A6 mRNA水平高于非肿瘤组织,其增加与淋巴结转移和患者生存时间缩短相关。结论认为SLC39A6表达增加与肿瘤侵袭性、细胞内锌水平和患者生存时间相关,过表达SLC39A6的ESCC细胞系上调MMP1、MMP3、MYC和SLUG并在小鼠中形成转移性异种移植瘤,SLC39A6上调可能用于判断ESCC患者预后或作为治疗靶点。
要点
- 敲低SLC39A6降低ESCC细胞增殖和小鼠异种移植瘤转移。
- 过表达SLC39A6增加细胞内锌水平、侵袭性,激活PI3K至AKT1和MAPK1信号。
- ESCC组织中SLC39A6 mRNA高于非肿瘤组织,其增加与淋巴结转移和生存时间缩短相关。
核心结论
- 在ESCC样本和细胞系分析中,SLC39A6表达增加与肿瘤侵袭性、细胞内锌水平和患者生存时间相关。
- 过表达SLC39A6的ESCC细胞系上调MMP1、MMP3、MYC和SLUG并在小鼠中形成转移性异种移植瘤。
- SLC39A6上调可能用于判断ESCC患者预后或作为治疗靶点。
研究设计与样本
- 在ESCC细胞(KYSE30和KYSE450)和HeLa细胞中用慢病毒载体表达短发夹RNA过表达或敲低SLC39A6,分析体外增殖、集落形成、迁移和侵袭。
- 细胞在裸鼠中生长为异种移植瘤,量化肿瘤体积和转移,收集肿瘤进行组织学分析。
- 分析细胞内锌水平和信使RNA(mRNA)表达模式。
- 获取2010年至2014年在中国接受食管切除术的94例患者的ESCC及癌旁正常食管组织。
- 从诊断日期至末次随访或死亡日期测量患者生存时间,用Wilcox秩和检验比较肿瘤与非肿瘤组织mRNA水平,用免疫印迹法测量细胞系或组织样本总蛋白,并检索公共数据库中人肿瘤和非肿瘤组织中SLC39A6变异。
主要发现
- 敲低SLC39A6降低培养中ESCC细胞增殖和小鼠异种移植瘤转移。
- 过表达SLC39A6的细胞细胞内锌水平显著增加,在实验中侵袭性更强,激活磷脂酰肌醇3-激酶信号至AKT丝氨酸/苏氨酸激酶1和丝裂原活化蛋白激酶1。
- 过表达SLC39A6的细胞转移相关mRNA和蛋白(如基质金属蛋白酶(MMP)1、MMP3、MYC和snail家族转录抑制因子2(SNAI2或SLUG))表达增加。
- 患者ESCC样本中MMP1、MMP3、MYC和SLUG mRNA水平与SLC39A6 mRNA水平相关。
- ESCC组织SLC39A6 mRNA水平高于非肿瘤组织,其增加与肿瘤淋巴结转移和患者生存时间缩短相关。
临床怎么用
- 作者认为SLC39A6上调可能用于判断ESCC患者预后或作为治疗靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A common variant in the solute carrier family 39 member 6 gene (SLC39A6) has been associated with survival times of patients with esophageal squamous cell carcinoma (ESCC). We investigated the function of SLC39A6 and ways in which this variant affects tumor progression by studying ESCC samples and cell lines. METHODS: SLC39A6 was expressed or knocked down by expression of short hairpin RNAs in ESCC cells (KYSE30 and KYSE450) and HeLa cells using lentiviral vectors; we analyzed effects on proliferation, colony formation, migration, and invasion in vitro. Cells were grown as xenograft tumors in nude mice and tumor volume and metastases were quantified; tumors were collected and analyzed histologically. Cells were also analyzed for levels of intracellular zinc and messenger RNA (mRNA) expression patterns. We obtained ESCC and adjacent normal esophageal tissues from 94 patients who underwent esophagectomy in China from 2010 through 2014. Survival times of patients were measured from the date of diagnosis to the date of last follow-up or death. We sequenced mRNAs and compared levels between tumor and non-tumor tissues using the Wilcox rank-sum test. Total proteins in cell lines or tissue samples were measured by immunoblotting. We searched publicly available databases for variants of SLC39A6 in human tumor and non-tumor tissues. RESULTS: Knockdown of SLC39A6 reduced proliferation of ESCC cells in culture and metastasis of xenograft tumors in mice. Cells that overexpressed SLC39A6 had significant increases in intracellular levels of zinc and were more invasive in assays, activating phosphatidylinositol 3-kinase signaling to AKT serine/threonine kinase 1 and mitogen-activated protein kinase 1. Cells that overexpressed SLC39A6 had increased expression of mRNAs and proteins associated with metastasis, such as matrix metalloproteinase (MMP) 1, MMP3, MYC, and snail family transcriptional repressor 2 (SNAI2 or SLUG). Levels of MMP1, MMP3, MYC, and SLUG mRNAs correlated with levels of SLC39A6 mRNA in ESCC samples from patients. ESCC tissues had increased levels of SLC39A6 mRNA compared with non-tumor tissues; the increase correlated with tumor metastasis to lymph node and reduced patient survival time. CONCLUSIONS: In an analysis of ESCC samples and cell lines, we associated increased expression of SLC39A6 with tumor invasiveness, intracellular level of zinc, and patient survival time. ESCC cell lines that overexpress SLC39A6 up-regulate expression MMP1, MMP3, MYC, and SLUG and form metastatic xenograft tumors in mice. Up-regulation of SLC39A6 might be used to determine prognoses of patients with ESCC or as a therapeutic target.
引用
- Cheng X, Wei L, Huang X, et al. Solute Carrier Family 39 Member 6 Gene Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-Kinase Signaling, and Up-regulating Genes That Regulate Metastasis. Gastroenterology. 2017. PMID: 28209530. doi:10.1053/j.gastro.2017.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。